CJ

Chelsea Johnson

Principal at Atlas Venture

Greater Boston

Overview 

Chelsea Johnson is a Principal at Atlas Venture in Greater Boston, with a background in genetics and oncology. Her career highlights include serving as an Associate Director of Business Development and Strategy at Tango Therapeutics and holding roles at Third Rock Ventures and Harvard Medical School. Chelsea Johnson's expertise in genetics and oncology has led to impactful roles such as Associate Director at Tango Therapeutics and Senior Associate at Third Rock Ventures, culminating in her current position as Principal at Atlas Venture in Greater Boston.

Work Experience 

AV

Atlas Venture

  • Principal

    2021 - Current

  • Senior Associate

    2019 - 2021

    Atlas Venture is a leading biotech venture capital firm. With the goal of doing well by doing good, we have been building breakthrough biotech startups since 1993. We work side by side with exceptional scientists and entrepreneurs to translate high impact science into medicines for patients. Our seed-led venture creation strategy rigorously selects and focuses investment on the most compelling opportunities to build scalable businesses and realize value. For more information, please visit www.atlasventure.com.

Atlas Venture creates and invests in biotech startup companies with seed and early stage venture investments.

atlasventure.com
KT

K36 Therapeutics, Inc.

  • Board Observer

    2021

K36 Therapeutics translate epigenetic modulation of oncogenic pathways into small molecule therapies.

Raised $100,000,000.00 from Bristol-Myers Squibb, F-Prime Capital, Nextech Invest, Eight Roads Ventures and Atlas Venture.

k36tx.com
RP

Rectify Pharma

  • Board Observer

    2020

Rectify Pharmaceuticals is a biotechnology company developing Positive Functional Modulators (PFMs), disease-modifying therapeutics.

Raised $100,000,000.00 from Forbion Capital Partners, Longwood Fund, Omega Funds and Atlas Venture.

rectifypharma.com
ST

Scorpion Therapeutics

  • Board Observer

    2020

Scorpion Therapeutics is a clinical-stage oncology company that specializes in precision medicine for cancer patients.

Raised $420,000,000.00 from Lightspeed Venture Partners, Invus, EcoR1 Capital, Boxer Capital, Surveyor Capital, Fidelity, Logos Capital, Atlas Venture, Casdin Capital and Nextech Invest.

scorpiontx.com
TT

Tango Therapeutics

  • Associate Director Business Development and Strategy

    2017 - 2019

Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.

Raised $351,000,000.00 from Casdin Capital, RA Capital Management, Woodline Partners, Boxer Capital, EcoR1 Capital, Surveyor Capital, Farallon Capital Management, Avoro Capital Advisors, Gilead Sciences and Samsara BioCapital.

tangotx.com
TR

Third Rock Ventures

  • Senior Associate

    2016 - 2017

  • Associate

    2015 - 2016

HM

Harvard Medical School

  • Graduate Student Researcher

    2010 - 2015

    Dissertation topic: Genomic and Functional Studies of Uveal Melanoma

DC

Dartmouth College

  • Undergraduate Student Researcher

    2007 - 2010

    Senior Honors Thesis Title: "Id4 is required for adipocyte differentiation"

NI

Novartis Institutes for BioMedical Research

  • Oncology Intern

    2009 - 2009

Education 

Articles About Chelsea

Relevant Websites